Resveratrol is efficiently glucuronidated by UDP-glucuronosyltransferases in the human gastrointestinal tract and in Caco-2 cells

Biopharmaceutics and Drug Disposition

Volumn 27, Issue 4, 2006, Pages 181-189

  Sabolovic, Nicole ^a   Humbert, Anne Claude ^a   Radominska Pandya, Anna ^b   Magdalou, Jacques ^a  

^a Biopôle de l Université de Lorraine   (France)

^b UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Caco 2 cells; Gastrointestinal tract; Resveratrol; UDP glucuronosyltransferases

Indexed keywords

GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A1; GLUCURONOSYLTRANSFERASE 1A10; GLUCURONOSYLTRANSFERASE 1A6; GLUCURONOSYLTRANSFERASE 1A8; ISOENZYME; POLYPHENOL DERIVATIVE; RESVERATROL; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CELL STRAIN CACO 2; CIS ISOMER; COLON; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; DRUG STRUCTURE; DUODENUM; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; HUMAN; HUMAN CELL; HUMAN TISSUE; INTESTINE CELL; MALE; MICROSOME; PROTEIN EXPRESSION; SCHOOL CHILD; SMALL INTESTINE; STEREOISOMERISM; STOMACH; TRANS ISOMER;

CACO-2 CELLS; GASTROINTESTINAL TRACT; GLUCURONIDES; GLUCURONOSYLTRANSFERASE; HUMANS; LIVER; MICROSOMES; STILBENES;

EID: 33744503133     PISSN: 01422782     EISSN: 1099081X     Source Type: Journal    
DOI: 10.1002/bdd.498     Document Type: Article

References (42)

1. Goldberg DM, Hahn SE, Parkes JG. Beyond alcohol-beverage consumption and cardiovascular mortality. Clin Chim Acta 1995; 237: 155-187.
2. McMurtrey KD. Resveratrol in wine. Acs Sympos Series 1997; 66: 44-55.
3. Dugo G, Salvo F, Dugo P, la Torre GL, Modello L. Antioxidants in Sicilian wines: analytic and compositive aspects. Drugs Exp Clin Res 2003; 29: 189-202.
4. Lin JK, Tsai SH. Chemoprevention of cancer, cardiovascular disease by resveratrol. Proc Natl Sci Counc Repub China 1999; 23: 99-106.
5. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp Clin Res 1999; 25: 65-67.
6. Carbo N, Costelli P, Baccino FM, Lopez-Soriano FJ, Argiles JM. Resveratrol, a natural product present in wine, decreases tumor growth in a rat tumor model. Biochem Biophys Res Commun 1999; 254: 739-743.
7. Park JW, Choi YJ, Tang MA, et al. Chemopreventive agent resveratrol, a natural product derived from grapes, reversibly inhibits progression through S and G2 phases of the cell cycle in U937 cells. Cancer Lett 2001; 163: 43-49.
8. Delmas D, Passilly Degrace P, Jannin B, Cherkaoui-Malki M, Latruffe N. Resveratrol a chemopreventive agent disrupts the cell cycle control of human SW 480 colorectal tumor cells. Int J Mol Med 2002; 10: 193-199.
9. Savouret JF, Quesne M. Resveratrol, cancer: a review. Biomed Pharmacother 2002; 56: 84-87.
10. Casper RF, Quesne M, Rogers IM, et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: Implications for prevention of dioxin toxicity. Mol Pharmacol 1999; 56: 784-790.
11. Savouret JF, Casper RF. The aryl hydrocarbon receptor and its xenobiotic ligands: a fundamental trigger for cardiovascular diseases. Nutr Metab Cardiovasc Dis 2003; 13: 104-113.
12. Gescher AJ, Steward WP. Relationship between mechanisms, bioavailability, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol Biomark Prev 2003; 12: 953-957.
13. Kuhnle G, Spencer JPE, Chowrimootoo G, et al. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem Biophys Res Commun 2000; 272: 212-217.
14. Radominska-Pandya A, Czernik PJ, Little J, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817-899.
15. Aumont V, Krisa S, Battaglia E, et al. Regioselective and stereospecific glucuronidation of trans- and cis-resveratrol in human. Arch Biochem Biophys 2001; 393: 281-289.
16. Radominska-Pandya A, Little JM, Pandya JT, et al. UDP-Glucuronosyltransferases in human intestinal mucosa. Biochim Biophy Acta 1998; 1394: 199-208.
17. Cheng Z, Radominska-Pandya A, Tephly TR. Studies on the substrate specificity of human intestinal UDP-glucuronosyltransferases 1A8 and 1A10. Drug Metab Dispos 1999; 27: 1165-1170.
18. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol 2001; 40: 405-414.
19. Czernik PJ, Little JM, Barone GW, Raufman J-P, Radominska-Pandya A. Glucuronidation of estrogens and retinoic acid and expression of UDP-glucuronosyltransferase 2B7 in human intestinal mucosa. Drug Metab Dispos 2000; 28: 1210-1216.
20. Waffo Teguo P, Decendit A, Krisa S, Deffieux G, Vercauteren J, Merillon JM. The accumulation of stilbene glycosides in Vitis vinifera cell suspension cultures. J Nat Prod 1996; 59: 1189-1191.
21. Radominska-Pyrek A, Zimniak P, Irshaid YM, Lester R, Tephly TR, Pyrek JS. Glucuronidation of 6 alpha-hydroxy bile acids by human liver microsomes. J Clin Invest 1987; 80: 234-241.
22. Hogeboom GH. Fractionation of cells components of animal tissues: general method for isolation of liver components. Methods Enzymol 1955; 1: 16-19.
23. Bradford M. A rapid, sensitive method for quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976; 72: 248-254.
24. Chantret I, Rodolosse A, Barbat A, et al. Differential expression of sucrase-isomaltase in clones isolated from early and late passages of the cell line Caco-2: evidence for a glucose-dependent negative regulation. J Cell Sci 1994; 107: 213-225.
25. Dragacci S, Thomassin J, Magdalou J, Souhaili-El-Amri H, Boissel P, Siest G. Properties of human hepatic UDP-glucuronosyltransferases: relationship to the other inducible enzymes in patients with cholestasis. Eur J Clin Pharmacol 1987; 32: 485-491.
26. Walle T, Hsieh F, DeLegge MH, Oatis JE Jr, Walle K. High absorption by very low bioavailability of oral resveratrol in humans. Drug Metab Dispos 2004; 32: 1377-1382.
27. Andlauer W, Kolb J, Siebert K, Furst P. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp Clin Res 2000; 26: 47-55.
28. Strassburg CP, Kniep S, Topp J, et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 2000; 275: 36164-36171.
29. Antonio L, Xu J, Little JM, Burchell B, Magdalou J, Radominska-Pandya A. Glucuronidation of catechols by human hepatic, gastric, and intestinal microsomal UDP-glucuronosyltransferases (UGT) and recombinant UGT1A6, UGT1A9, and UGT2B7. Arch Biochem Biophys 2003; 411: 251-261.
30. Sabolovic N, Heydel JM, Li X, et al. Carboxyl non steroidal anti-inflammatory drugs are efficiently glucuronidated by microsomes of the human gastrointestinal tract. Biochim Biophys Acta 2004; 1675: 120-129.
31. Gregory PA, Lewinsky RH, Gardner-Stephen DA, Mackenzie PI. Regulation of UDP-glucuronosyltransferases in the gastrointestinal tract. Toxicol Appl Pharmacol 2004; 3: 354-363.
32. Radominska-Pandya A, Pokrovskaya ID, Xu J, et al. Nuclear UDP-glucuronosyltransferases: identification of UGT2B7 and UGT1A6 in human liver nuclear membranes. Arch Biochem Biophys 2002; 399: 37-48.
33. Li Y, Shin YG, Yu C, et al. Increasing the throughput and productivity of Caco-2 cell permeability assays using liquid chromatography-mass spectrometry: application to resveratrol absorption and metabolism. Comb Chem High Throughput Screen 2003; 6: 757-767.
34. Kaldas MI, Walle UK, Walle T. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J Pharm Pharmacol 2003; 55: 307-312.
35. Münzel PA, Schmohl S, Heel H, Kalberer K, Bock-Hennig BS, Bock KW. Induction of human UDP-glucuronosyltransferases (UGT1A6, UGT1A9, and UGT2B7) by t-butylhydroquinone and 2,3,7,8-tetrachlorodibenzo-p-dioxin in Caco-2 cells. Drug Metab Dispos 1999; 27: 569-573.
36. Sabolovic N, Magdalou J, Netter P, Abid A. Nonsteroidal anti-inflammatory drugs and phenols glucuronidation in Caco-2 cells: Identification of the UDP-glucuronosyltransferases UGT1A6, 1A3 and 2B7. Life Sci 2000; 67: 185-196.
37. Jeong EJ, Liu Y, Hu M. Species- and disposition model-dependent metabolism of raloxifene in gut and liver: role of UGT1A10. Drug Metab Dispos 2005; 33: 1-10.
38. Abid A, Bouchon I, Siest G, Sabolovic N. Glucuronidation in the Caco-2 intestinal cell line: induction of UDP-glucuronosyltransferase 1A 6. Biochem Pharmacol 1995; 50: 557-561.
39. Mizuma T, Momota R, Haga M, Hayashi M. Factors affecting glucuronidation activity in Caco-2 cells. Drug Metab Pharmacokinet 2004; 19: 130-134.
40. Schneider Y, Vincent F, Duranton B, et al. Anti-proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett 2000; 158: 85-91.
41. Lampen A, Ebert B, Stumkat L, Jacob J, Seidel A. Induction of gene expression of xenobiotic metabolism enzyme and ABC-transport proteins by PAH and a reconstituted PAH mixture in human Caco-2 cells. Biochim Biophys Acta 2004; 1681: 38-46.
42. Potter GA, Patterson LH, Wanogho E, et al. The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1. Br J Cancer 2002; 86(5): 774-778.